| Literature DB >> 35350652 |
Murong Xu1,2, Mingpeng Zhao1, Raymond Hang Wun Li3, Zhixiu Lin4, Jacqueline Pui Wah Chung1, Tin Chiu Li1, Tin-Lap Lee2, David Yiu Leung Chan1.
Abstract
Objective: To summarize the currently available phase I and II clinical trials of the effects of nonoxynol-9 (N-9) on human sperm structure and functions.Entities:
Keywords: Nonoxynol-9; progressive motility; sperm function; spermicide; vanguard sperm penetration distance
Mesh:
Substances:
Year: 2022 PMID: 35350652 PMCID: PMC8956826 DOI: 10.1530/RAF-21-0024
Source DB: PubMed Journal: Reprod Fertil ISSN: 2633-8386
Spermicide products containing N-9. Various deliver-9 products with different delivery systems and dosage options of N-9 are shown in the table, together with the directions for use.
| Product | Form | Content | Required insert time | Instruction | Duration | Availability |
|---|---|---|---|---|---|---|
| VCF® | Film | 28% | 15 min | In contact with the cervix | Last for 3 h | Available |
| VCF® | Foam | 12.5% | Less than 1 h; works immediately | Insert into vagina; wait at least 6 h for douching | – | Available |
| VCF® | Gel | 4% | Works immediately | Insert into vagina | Up to 1 h | Available |
| Gynol II® | Gel | 3% | Works immediately | Insert into vagina | Up to 1 h | Available |
| Conceptrol® | Gel | 4% | Works immediately | Insert into vagina | Up to 1 h | Available |
| ContraSeed® | Suppository | 100 mg | 15 min | Insert and lie against the cervix | Up to 1 h | Available |
| Today® | Sponge | 1000 mg | Works immediately | Wet sponge thoroughly and squeeze gently until sudsing; fold with dimple side inside; insert deeply into vagina with string loop on bottom end; wait 6 h before removing and avoid inserting for >30 h | 24 h | Available |
| Encare® | Suppository | 100 mg | At least 10 min | Insert into vagina; wait at least 6 h for douching | Up to 1 h | Not available |
| Advantage 24® | Gel | 3.5% | Less than 30 min | Insert into vagina; release steadily in the bioadhesive delivery system attaching to the vaginal epithelial surface | 24 h | Not available |
| Shur-Seal® | Gel | 2% | At least 10 min; works immediately | Insert into vagina; wait at least 6 h for douching | – | Not available |
| Delfen® | Foam | 12.5% | Up to 1 h | Insert into vagina; wait at least 6 h for douching | – | Not available |
Figure 1Flowchart of study selection for the systematic review.
Characteristics of the included studies. We included 11 eligible articles and summarized the characteristics of the mode, semen specimen information, sample size, intervention concentration, control, and duration. Reported sperm parameters included progressive motility in cervical mucus and vanguard sperm penetration distance. Values are mean ± s.d. or as specified.
| Reference | Mode | Sperm characteristics | Sample size | Duration ( | Control | Intervention concentration | Reported sperm parameters (mm) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Concentration | Motility | Treated | Control | Treated | Control | Treated | Control | ||||
| Vanguard sperm penetration distances | |||||||||||
| Sharman | >40 × 106/mL | >60% | 3 | 3 | 2 | Tyrode’s solution | % | % | |||
| 0.033 mg/mL | 28.2 ± 4.1 | 27.3 ± 4.1 | |||||||||
| 0.33 mg/mL | 13.4 ± 1.77 | 27.3 ± 4.1 | |||||||||
| 3.3 mg/mL | 7.86 ± 2.3 | 27.3 ± 4.1 | |||||||||
| Dunmire & Katz (1997 | >40 × 106/mL | >55% | 4 | 4 | >2 | 3 | Water | 100 mg/mL | 41.5 ± 1.0 | 44.2 ± 0.3 | |
| Dunmire & Katz (1997 | >40 × 106/mL | >55% | 10 | 10 | >2 | 3 | 100 mg/mL | % | % | ||
| Water | 40.4 ± 6 | 45.7 ± 4.1 | |||||||||
| Saline | 44.0 ± 2.8 | 49.3 ± 5.1 | |||||||||
| | >100 × 106/mL | >50% | 5 | 5 | 4 | Saline | 5 mg/mL | 2 ± 0.4 | 39 ± 6.7 | ||
| PR sperm count/HPF | |||||||||||
| Mauck | PCT | – | 10 | 10 | 2.5 ± 0.4 | 2.5 ± 0.6 | PB | VCF® (70 mg N-9) | 0±0 | 22.2 ± 20.2 | |
| Mauck | PCT | – | 10 | 10 | PB | % | % | ||||
| 2.8 ± 0.5 | 2.5 ± 0.5 | VCF® (70 mg N-9) | 0.5 ± 0.8 | 23.7 ± 26.7 | |||||||
| 2.1 ± 0.5 | 2.5 ± 0.5 | 100 mg N-9 | 0.6 ± 0.9 | 23.7 ± 26.7 | |||||||
| 2.5 ± 0.5 | 2.5 ± 0.5 | 130 mg N-9 | 0.9 ± 2.3 | 23.7 ± 26.7 | |||||||
| Mauck | PCT | – | 7 | 7 | PB | % | % | ||||
| 2.3 ± 0.4 | 2.5 ± 0.4 | Femcap® with N-9 | 0.2 ± 0.4 | 18.0 ± 20.5 | |||||||
| 2.6 ± 0.3 | 2.5 ± 0.4 | Diagram with N-9 | 0 ± 0 | 18.0 ± 20.5 | |||||||
| | PCT | >20 × 106/mL | 5 | 9 | <3 h | PB | Protectaid® sponge (0.125%N-9) | 0.6 ± 1.1 | 17.8 ± 7.2 | ||
| Amaral | PCT | – | 20 | 20 | <2 h | PB | 2% N-9 | 0.07 ± 0.23 | 17.94 ± 19.91 | ||
| Schwartz | PCT | 2–3 h | PB | % | % | ||||||
| – | 13 | 14 | SILCS (metal)+N-9 | 0 ± 0 | 12.5 ± 8.8 | ||||||
| – | 8 | 14 | SILCS (polymer spring)+N-9 | 0 ± 0 | 12.5 ± 8.8 | ||||||
| Mauck | PCT | – | 9 | 9 | 2–3 h | PB | Caya®+3% N-9 | 0.6 ± 1.1 | 22.5 ± 33.4 | ||
PB, personal baseline; PR, progressively motile; PCT, postcoital tests.
Risk of bias assessment using ROBINS-I. The quality of the included papers was evaluated by the ROBINS-I tool using the judgment of ‘low’, ‘moderate’, and ‘high’ risk. The overall biases of all the papers included were considered at low risks.
| Sharman | Dunmire & Katz (1997 | Dunmire & Katz (1997 | Mauck | Mauck | Mauck | Amaral | Schwartz | Mauck | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bias due to confounding | L | L | L | L | L | L | L | L | L | L | L |
| Bias in selection of participants into the study | L | L | L | L | L | L | L | L | L | L | L |
| Bias in classification of interventions | L | L | L | L | L | L | L | L | L | L | L |
| Bias due to deviations from intended interventions | L | L | L | L | L | L | L | H | L | L | L |
| Bias due to missing data | L | L | L | L | L | L | L | L | L | H | L |
| Bias in measurement of outcomes | L | L | L | L | L | L | L | L | L | L | L |
| Bias in selection of the reported result | L | L | L | L | L | L | L | L | L | L | L |
| Overall | L | L | L | L | L | L | L | L | L | L | L |
L, low risk; M, moderate risk; H, high risk.
Figure 2Meta-analysis forest plots and funnel plots.
Summary of the functional mechanisms of N-9 on sperm. The table showed the studies focusing on the effects of N-9 on the viability, motility characteristics, acrosome intactness, acrosin activity, sperm membrane, other organelles, and other aspects of human sperm.
| Reference | Sperm | Sample size | N-9 concentration | Descriptions of the effect of N-9 | |
|---|---|---|---|---|---|
| Concentration | Motility | ||||
| Viability | |||||
| Jain | >65 × 106/mL | >70% | – | 500 μg/mL | Necrosis in nearly 90% of sperm; viable sperm cell populations fell to ~2%. |
| Shah | – | – | 10 | – | Near 0% viability at 0.08 mg/mL. |
| Ping | >15 × 106/mL | – | 15 | 0.5, 0.25, 0.125, and 0.0625 mg/mL | 0% viability within 30 min at ≥0.25 mg/mL; 0% viability within 20 s at 0.5mg/mL |
| Jain | >60 × 106/mL | >75% | – | – | Necrosis induction in a significant number of sperm nonspecifically. |
| Motility characteristics | |||||
| | – | 6 | 2000, 1000, 100, 20, 10 μg/mL | 0% motility at 2000–20 μg/mL, 6.5 ± 5.74% motility at 10 μg/mL; 0 progressive velocity at all doses except at 10 μg/mL (8.2 ± 5.5), with a significant decrease compared to fresh (46.7 ± 4.03); significant decrease of hyperactivation by N-9 (0–0.3 ± 0.3%). | |
| | >60 × 106/mL | >50% | 6 | 0, 15, 30, 45, and 60 μg/mL | Significant decreases in motility, LIN, and VSL ( |
| Dunmire & Katz (1997 | >40 × 106/mL | >55% | 9 | – | Significant decrease in MOT ( |
| | >100 × 106/mL | >50% | 5 | 5 mg/mL | Very significant effect on all sperm motility characteristics, VCL, ALH, and LIN ( |
| Zaïri | – | 20 | 5–200 μg/mL | 0% motility at ≥100 μg/mL. | |
| Zairi | – | 50 | 0–500 μg/mL | 0% motility at ≥100 μg/mL. | |
| White | >20 × 106/mL | >40% | >50 | 5, 50, and 500 μg/mL | No significant effect on human sperm motility at 5 μg/mL; significant (P < 0.01) reduction of motility at 50 μg/mL; complete stop in all sperm movement within 1 min at 500 μg/mL. |
| | – | 8 | – | Significant effect on sperm motility at a dose of 50 µM. | |
| | – | 6 | – | Decreased motility with the increasing concentration. | |
| Lee | >20 × 106/mL | >50% | – | 0.050, 075, 0.1, 0.125, 0.15, and 0.175 mg/mL | Decreased motility with the increasing concentration. |
| | >15 × 106/mL | >40% | 5 | 0.2, 0.4, and 0.6 mg/mL | 0% motility at ≥0.4 mg/mL. |
| Shah | – | 10 | – | Decreased motility with the increasing concentration. | |
| Ping | >15 × 106/mL | 15 | 0.5, 0.25, 0.125, and 0.0625 mg/mL | 0% motility at ≥0.25 mg/mL within 20 s; 0% motility at ≥0.125 mg/mL in 30 min. | |
| Acrosome intactness and acrosin activity | |||||
| | – | 6 | 2000, 1000, 100, 20, and 10 μg/mL | Complete break down and release of the acrosomal contents at all doses (16 ± 2.6–26 ± 6.0% RITC+; 73.3 ± 4.8–83.7 ± 2.6% RITC−). | |
| | >15 × 106/mL | >40% | 44 | 0.2, 0.4, and 0.6 mg/mL | Loss of the acrosomal structure. |
| Xia | – | 40 mg/mL | No intact acrosome from a weak fluorescence strap that appeared in the equatorial zone. | ||
| Wilborn | – | 30 | 0.05, 0.1, 0.25, 0.5, 1.0, 2.5, 5.0, and 10.0% | Damage in acrosomal membrane complex, which ranged from vesiculations to complete obliteration; not always affected post-acrosomal membrane. | |
| | – | – | 0.05% | Missed acrosomal membrane complex including equatorial segment. | |
| | – | – | 0.05–1% | Gelatin film method (acrosin activity): complete prevention gelatin lysis at 0.05–1% N-9; moderate halo formation at 0.001–0.01%; completely missed halo formation at 0.05–1%. | |
| Sperm membrane and other organelles | |||||
| | >15 × 106/mL | >40% | 44 | 0.2, 0.4, and 0.6 mg/mL | Severely damaged membrane organization; partial dissolution of plasma membrane; partly exposed nucleus. |
| Jain | >65 × 106/mL | >70% | – | 500 μg/mL | Significant ( |
| Xia | – | – | 40 mg/mL | Rare appearance of spermatozoa with a swollen tail; deconstruction of membrane permeability; leakage of cytoplasm. | |
| Wilborn | – | 30 | 0.05, 0.1, 0.25, 0.5, 1.0, 2.5, 5.0, and 10.0% | Destruction of the cell membrane of the neck; absence of midpiece membrane; extirpated mitochondria of the midpiece and exposed fibers in approximately 25% of sperm; vesiculations as the first evidence of all membrane damage; loose and detached membranes then; membrane of the tail not always affected. | |
| Thompson | – | – | 0.01, 0.02, 0.03, and 0.04% | Increase of sperm cell permeabilization. | |
| Shah | – | 10 | – | Membrane perturbation and disruption. | |
| | – | – | 0.05% | Completely removed plasma membrane from head to the end piece; appearance of swollen, break, discontinuous nuclear membrane; enlarged space between the nucleus and the nuclear membrane; swollen chromatin structures in some sperm and nuclear decondensation in others; missed cytoplasm in the neck region and the middle piece; appearance of monolayer membrane of the mitochondria instead of bilaminar membrane; empty interior of the mitochondria or containing a fine granular material and disappearance of normal cristae. | |
| Lakshmi | >60 × 106/mL | >75% | – | 0.05% | Physiological damage of sperm membrane. |
| Others | |||||
| Jain | >65 × 106/mL | >70% | – | 500 μg/mL | |
Linearity-LIN, Straight line velocity-VSL, Mean angular displacement-MAD, Curvilinear velocity-VCL, Motility- MOT, Amplitude of lateral head displacement-ALH, Rhodamine isothio- cyanate conjugated-RITC, Reactive Oxygen Species-ROS, Superoxide dismutase-SOD.